Bioventus Reports Q3 2026 Growth in Pain Treatments and Improved EBITDA Margins
Bioventus (BVS) reported third-quarter revenue of $142.4 million, a 3% year-over-year increase driven largely by its Pain Treatments segment. The company saw significant margin expansion, with Adjusted EBITDA reaching $28.4 million and an Adjusted EBITDA margin of 20%, up 70 basis points from the previous year. Non-GAAP earnings per share rose 13% to $0.17, aided by reduced interest expenses. While international revenue grew strongly at 16.4%, certain segments faced headwinds. Restorative Therapies declined due to sales force vacancies, and Bone Graft Substitutes saw a 6% dip caused by softness in spine procedures and distributor delays. Despite these challenges, the company is aggressively reducing debt, with net debt falling below $200 million following $65 million in year-to-date repayments.
Tickers: $BVS
Topics: Debt Reduction EBITDA Pain Treatments Segment Revenue Growth